NSRX - Nasus Pharma Ltd. News

Discover

NSRX

Nasus Pharma Ltd.

3.29

1 x 3.16

1 x 3.50

bid

ask

0.06

1.79%

01:24 PM

timesize

Ytd	-64.04%
1y	-60.12%

3.29

day range

3.40

1.98

52 week range

9.99

Open	3.40	Prev Close	3.35	Low	3.29	High	3.40	Mkt Cap	28.34M
Vol	2.08K	Avg Vol	27.79K	EPS	-0.72	P/E	-4.57	Forward P/E	N/A
Beta	N/A	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	N/A	50-d Avg	3.17	200-d Avg	4.72	1yr Est	0.00

NSRX News

defenseworld.net

Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report)'s share price was up 9.7% during mid-day tra

benzinga.com

Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a

globenewswire.com

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer

TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus

globenewswire.com

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” o

globenewswire.com

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intrana

Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic

globenewswire.com

Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphy

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” o

globenewswire.com

Nasus Pharma to Participate in Upcoming Investor Conferences

TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

globenewswire.com

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results

Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery,

globenewswire.com

BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcri

In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from i

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com

What's Going On With Nasus Pharma Stock On Wednesday

The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demon

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

Crude Oil Down 4%; Dollar Tree Earnings Top Views

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

globenewswire.com

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Signifi

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compare

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

globenewswire.com

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

globenewswire.com

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

globenewswire.com

Nasus Pharma to Participate in Upcoming Investor Conferences

TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "C

globenewswire.com

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epin

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "

globenewswire.com

Nasus Pharma Announces Closing of $15.0 Million Private Placement

TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "C

globenewswire.com

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" o

globenewswire.com

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epin

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephr

globenewswire.com

Nasus Pharma CEO Issues 2025 Letter to Shareholders

TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma",

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session